Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)

Figure 1

PHA-739358 decreases viability of human and mouse lymphoblastic leukemia cells. Human acute lymphoblastic leukemia cells including BLQ1, Pt2 (Bcr/Abl+, T315I mutation), UCSF02, TXL2 (Bcr/Abl+, wild type), US7, US7R (non-Bcr/Abl) and mouse Bcr/Abl+ 8093 and Bin2 leukemia cells were cultured in the presence of stroma. Viable cell counts were determined by Trypan blue exclusion assay after treatment for 72 hours with the indicated amounts of PHA-739358. Error bars indicate SD. Results shown are one of two independently performed experiments in triplicate with similar results. (*p < 0.05, **p <0.001).

Back to article page

Molecular Cancer

ISSN: 1476-4598